
The iShares iBonds Dec 2027 Term Corporate ETF aims to replicate the investment performance of an underlying index, which consists of high-quality corporate debt securities issued in U.S. dollars and scheduled to mature in 2027. This Fund's operational framework is also protected by U.S. Patent Numbers 8,438,100 and 8,655,770.
Is IBDS's expense ratio expensive, average, or a steal for its category?
Pro reveals the verdict on a 5-tier spectrum calibrated against ICI 2025 industry averages, with strategy-aware bands so the comparison is meaningful.

The sudden stop to markets induced by COVID-19 caused a substantial repricing of credit risk globally, and central banks, treasuries, and ministries of finance around the world responded unequivocally.

We downgrade investment grade credit to neutral and increase our overweight in high yield as we see volatility rising after a rally in risk assets.

We examine the effects of the crisis on the year-to-date liquidity of USD corporate bonds, as measured by the price liquidity ratio. The price liquidity ratio c

This is a weekly series focused on analyzing the previous week’s economic data releases. The objective is to concentrate on leading indicators of economic activ

Confluence Investment Management LLC lowered its stake in iShares iBonds Dec 2027 Term Corporate ETF (NYSEARCA:IBDS) by 18.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 395,388 shares of the company’s stock after selling 87,595 shares during the quarter. Confluence Investment Management LLC owned […]